Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Habte, Yimer"'
Autor:
Chris Yasenchak, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Paul Gonzales, Mihir Raval, Rangaswamy Chintapatla, Tatyana A. Feldman, Habte Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul D. Gandhi, John Renshaw, Linda Ho, Michelle Fanale, Wenchuan Guo, Hun Ju Lee
Publikováno v:
HemaSphere, Vol 7, p e5881312 (2023)
Externí odkaz:
https://doaj.org/article/6e8ef5b43868466087976545b54a69df
Autor:
Habte, Yimer, Jason, Melear, Edward, Faber, William I, Bensinger, John M, Burke, Mohit, Narang, Don, Stevens, Kathleen S, Gray, Yana, Lutska, Padma, Bobba, Keqin, Qi, Daniela, Hoehn, Ming, Qi, Thomas S, Lin, Robert M, Rifkin
Publikováno v:
Leukemia & Lymphoma. 63:2383-2392
In the primary analysis of LYRA, daratumumab + cyclophosphamide/bortezomib/dexamethasone (DARA + CyBorD) was effective and well tolerated in newly diagnosed multiple myeloma (NDMM) and relapsed multiple myeloma (RMM). We report the final analysis of
Autor:
Linlin Xu, Mazyar Shadman, Anusha Ponakala, Ian W. Flinn, Moshe Yair Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jennifer L. Cultrera, Jamal Misleh, Edwin C. Kingsley, Habte Yimer, Benjamin Freeman, Arvind Chaudhry, Praveen K. Tumula, Mitul Gandhi, Aileen Cohen, Dih-Yih Chen, Sudhir Manda, Jeff P. Sharman, Vanitha Ramakrishnan
Publikováno v:
Blood. 140:9269-9271
Autor:
Hun Lee, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Paul Alan Gonzales, Mihir Raval, Rangaswamy Chintapatla, Tatyana Feldman, Habte Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul Gandhi, John Renshaw, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Christopher A. Yasenchak
Publikováno v:
Blood. 140:763-765
Autor:
Yuliya Linhares, Cesar Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris, Daanish Hoda, Juan Carlos Varela, Courtney Bellomo, Scott Cross, James Essell, Suzanne Fanning, Howard Terebelo, Habte Yimer, Jay Courtright, Jeff P. Sharman, Min Vedal, Connor Mailley, Ricardo Espinola, Bassam Mattar
Publikováno v:
Blood. 140:10416-10418
Autor:
Spencer H Shao, Brian Allen, Jessica Clement, Gina Chung, Jingjing Gao, Earl Hubbell, Minetta C Liu, Charles Swanton, WH Wilson Tang, Habte Yimer, Mohan Tummala
Publikováno v:
Tumori.
There are four solid tumors with common screening options in the average-risk population aged 21 to 75 years (breast, cervical, colorectal, and, based on personalized risk assessment, prostate), but many cancers lack recommended population screening
Autor:
Tapan M. Kadia, Christopher Benton, Harry P. Erba, Mitul Gandhi, Moshe Y. Levy, Mary-Elizabeth M. Percival, Matthew Ulrickson, Habte Yimer, Min Yu, Zi Chen, Jing Wang, Mingyu Li, Mohammad Ahmad, Dajun Yang, Yifan Zhai
Publikováno v:
Blood. 140:11659-11660
Autor:
W H Wilson, Tang, Habte, Yimer, Mohan, Tummala, Spencer, Shao, Gina, Chung, Jessica, Clement, Bong Chul, Chu, Earl, Hubbell, Kathryn N, Kurtzman, Charles, Swanton, Lewis R, Roberts
Publikováno v:
Preventive Medicine. 167:107384
Disparities in cancer screening and outcomes based on factors such as sex, socioeconomic status, and race and ethnicity in the United States are well documented. A blood-based multi-cancer early detection (MCED) test that detects a shared cancer sign
Autor:
Habte Yimer, Ruemu Birhiray, Ralph Boccia, Sudhir Manda, Suman Kambhampati, Joshua Richter, Jack Aiello, Saulius Girnius, Dasha Cherepanov, Kim Tran, Presley Whidden, Stephen Noga, Robert Rifkin
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S147-S148
Autor:
John M. Burke, Jay Courtright, Miguel Islas-Ohlmayer, Ian W. Flinn, Sudhir Manda, Jacqueline Nielsen, Jeff P. Sharman, Dingfeng Jiang, John Pesko, Suzanne R. Fanning, Suman Kambhampati, Tamas Vizkelety, David Andorsky, Jason M. Melear, Kathryn Kolibaba Habte Yimer, Bertrand Anz, Simon Sharmokh
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S219-S220
Background/Aims Bcl-2 inhibitor venetoclax (VEN) has demonstrated efficacy in patients with chronic lymphocytic leukemia (CLL). As VEN induces rapid cell death, patients with medium- to high tumor burden (TB) are at greater risk for tumor lysis syndr